Merz Announces European Approval of Bocouture for the Treatment of Upper Facial Lines

Merz Pharma Group today announced that Bocouture® has been approved by European regulatory authorities for the treatment of upper facial lines, including horizontal frown lines, lateral periorbital lines and glabellar frown lines. Bocouture is the only neurotoxin approved in Europe* […]

Continue Reading

Treating Male Skin

by KAT WALES Practitioners discuss the skin concerns of their male patients and how they treat each indication Introduction The male grooming and cosmetic sector has never been bigger. The rise in the number of men having non-surgical aesthetic treatments […]

Continue Reading

Actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle

Abstract “We found a marked and dose-dependent positive effect of in vitro administration of Actovegin on mitochondrial function in human skeletal muscle” Actovegin, a deproteinized haemodialysate of calf blood, is suggested to have ergogenic properties, but this potential effect has […]

Continue Reading

Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH

Anti-cancer effects of vitamin C revisited Jiska van der Reest1 and Eyal Gottlieb1 1Cancer Metabolism Research Unit, Cancer Research UK, Beatson Institute, Glasgow, UK Correspondence: Eyal Gottlieb, E-mail: e.gottlieb@beatson.gla.ac.uk Vitamin C was first suggested to have cancer-fighting properties in the 1930s and […]

Continue Reading

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

Abstract BACKGROUND: Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin. STUDY DESIGN: Phase 2, randomized (3:1), open-label, active-comparator, safety and efficacy study. SETTING & PARTICIPANTS: Patients […]

Continue Reading

A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial

Source: http://www.ajkd.org/article/S0272-6386(15)01495-X/fulltext Background Anemia associated with chronic kidney disease (CKD) often requires treatment with recombinant human erythropoietin (EPO). Hypoxia-inducible factor−prolyl hydroxylase inhibitors (PHIs) stimulate endogenous EPO synthesis and induce effective erythropoiesis by non-EPO effects. GSK1278863 is an orally administered small-molecule PHI. […]

Continue Reading

Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry

Abstract GHRP-2 (pralmorelin, D-Ala-D-(beta-naphthyl)-Ala-Ala-Trp-D-Phe-Lys-NH(2)), which belongs to a class of growth hormone secretagogue (GHS), is intravenously used to diagnose growth hormone (GH) deficiency. Because it may be misused in expectation of a growth-promoting effect by athletes, the illicit use of […]

Continue Reading

Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin

Keywords: LC-MS/MS; growth hormone releasing peptides; metabolism; doping control; nasal administration Growth hormone releasing peptides (GHRPs) stimulate secretion of endogenous growth hormone and are listed on the World Anti-Doping Agency (WADA) Prohibited List. To develop an effective method for GHRPs […]

Continue Reading